Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Eli Lilly's Mounjaro Won't Have Separate Indication for Obstructive Sleep Apnea, European Regulator Says
EMA: Eli Lilly and Co (LLY.US) weight loss drug Mounjaro can also treat sleep apnea without the need for additional indications.
An expert panel of the EU pharmaceutical regulatory institution EMA has determined that Eli Lilly and Co's weight-loss drug Mounjaro does not require a separate indication for the treatment of obstructive sleep apnea (OSA).
Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.
Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease
Jefferies Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $994
